Chennai, Dec. 20
THE Chennai-based Orchid Chemicals & Pharmaceuticals Ltd will be able to tap a $117 million market in the US with launch of Cefprozil tablets (cephalosporin) after December 23, 2005, when its patent expires, according to a press release from the company.
This follows the approval of Orchid's Abbreviated New Drug Application (ANDA) by the US Food and Drug Administration (USFDA). The Cefprozil Tablets USP, 250 mg and 500 mg will be launched exclusively through Par Pharmaceuticals immediately after the expiry of the patent, the release said.
This is Orchid's eighth cephalosporin ANDA approval covering four cephalosporin products in various dosage forms. More are in the pipeline with Orchid having filed 21 ANDAs with the USFDA, the release said.
Quoting Orchid's Managing Director, Mr K. Raghavendra Rao, the release said that he was confident that Cefprozil would be a lead product in the distribution alliance with Par Pharmaceuticals in the US generics market and carve for itself a significant share in the oral cephalosporin generic formulations market in the future.